image
Healthcare - Medical - Diagnostics & Research - NASDAQ - US
$ 7.85
0.641 %
$ 1.7 B
Market Cap
-3.58
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one NEOG stock under the worst case scenario is HIDDEN Compared to the current market price of 7.85 USD, Neogen Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one NEOG stock under the base case scenario is HIDDEN Compared to the current market price of 7.85 USD, Neogen Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one NEOG stock under the best case scenario is HIDDEN Compared to the current market price of 7.85 USD, Neogen Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NEOG

image
$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
924 M REVENUE
12.37%
58.7 M OPERATING INCOME
56.37%
-9.42 M NET INCOME
58.81%
35.3 M OPERATING CASH FLOW
-14.05%
-29.3 M INVESTING CASH FLOW
-14.58%
1.92 M FINANCING CASH FLOW
101.62%
231 M REVENUE
6.59%
-457 M OPERATING INCOME
-20269.56%
-456 M NET INCOME
-3518.70%
40.3 M OPERATING CASH FLOW
324.70%
-17.2 M INVESTING CASH FLOW
49.03%
-1.41 M FINANCING CASH FLOW
-143.92%
Balance Sheet Neogen Corporation
image
Current Assets 589 M
Cash & Short-Term Investments 171 M
Receivables 173 M
Other Current Assets 245 M
Non-Current Assets 3.96 B
Long-Term Investments 229 K
PP&E 292 M
Other Non-Current Assets 3.67 B
3.76 %3.80 %5.39 %6.42 %80.62 %Total Assets$4.5b
Current Liabilities 154 M
Accounts Payable 83.1 M
Short-Term Debt 7.55 M
Other Current Liabilities 63.7 M
Non-Current Liabilities 1.25 B
Long-Term Debt 899 M
Other Non-Current Liabilities 352 M
5.91 %4.54 %63.98 %25.04 %Total Liabilities$1.4b
EFFICIENCY
Earnings Waterfall Neogen Corporation
image
Revenue 924 M
Cost Of Revenue 460 M
Gross Profit 464 M
Operating Expenses 405 M
Operating Income 58.7 M
Other Expenses 68.1 M
Net Income -9.42 M
1b1b900m900m800m800m700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)924m(460m)464m(405m)59m(68m)(9m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
50.19% GROSS MARGIN
50.19%
6.35% OPERATING MARGIN
6.35%
-1.02% NET MARGIN
-1.02%
-0.30% ROE
-0.30%
-0.21% ROA
-0.21%
0.88% ROIC
0.88%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Neogen Corporation
image
80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)201620162017201720182018201920192020202020212021202220222023202320242024
Net Income -9.42 M
Depreciation & Amortization 121 M
Capital Expenditures -111 M
Stock-Based Compensation 13.8 M
Change in Working Capital -72.7 M
Others -588 K
Free Cash Flow -76.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Neogen Corporation
image
Wall Street analysts predict an average 1-year price target for NEOG of $16.5 , with forecasts ranging from a low of $14 to a high of $17.5 .
NEOG Lowest Price Target Wall Street Target
14 USD 78.34%
NEOG Average Price Target Wall Street Target
16.5 USD 110.19%
NEOG Highest Price Target Wall Street Target
17.5 USD 122.93%
Price
Max Price Target
Min Price Target
Average Price Target
181817171616151514141313121211111010998877May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Neogen Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
419 K USD 2
3-6 MONTHS
251 K USD 2
6-9 MONTHS
124 K USD 1
9-12 MONTHS
7. News
Seeking Clues to Neogen (NEOG) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics Evaluate the expected performance of Neogen (NEOG) for the quarter ended February 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com - 2 weeks ago
Neogen Announces Third-Quarter Earnings Release Date LANSING, Mich. , March 20, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) will issue its third-quarter earnings release before the opening of the market on Wednesday, April 9, 2025. prnewswire.com - 1 month ago
NLRB Withdraws Unfair Labor Practices Claim Against Neogen® LANSING, Mich. , Feb. 18, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today the National Labor Relations Board (NLRB) has withdrawn its unfair labor practices claim against the Company. prnewswire.com - 2 months ago
Baron Small Cap Fund: Q4 2024 Top Contributors And Detractors Vertiv Holdings Co. excels with strong AI-related data center demand, projecting 16%-18% organic revenue growth for 2025, and increased profit margins. Chart Industries, Inc. shows robust fundamentals with record revenue and margins, expecting 12% revenue and 18% EBITDA growth in 2025. Intapp, Inc. benefits from strong quarterly results, 17% revenue growth, and a record pipeline, driven by AI product demand and favorable M&A activity. seekingalpha.com - 2 months ago
Neogen® Introduces Igenity® BCHF to Help Industry Mitigate Bovine Congestive Heart Failure Risk LINCOLN, Neb. , Jan. 21, 2025 /PRNewswire/ --  Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food security solutions, announced today the launch of Igenity® BCHF to improve overall bovine heart health standards. prnewswire.com - 2 months ago
NEOG Stock Gains Following the Launch of Its New MDA2QSAL96 Kit Neogen launches the new Molecular Detection Assay 2 - Quantitative Salmonella (MDA2QSAL96) to deliver consistency and sensitivity with an easy-to-use workflow that saves time and resources. zacks.com - 3 months ago
Neogen® Launches New MDA2 Quantitative Salmonella Molecular Detection Assay LANSING, Mich. , Jan. 16, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, announced today the launch of the new Neogen Molecular Detection Assay 2 – Quantitative Salmonella (MDA2QSAL96). prnewswire.com - 3 months ago
NEOG Prelim Q2 Earnings Meet, '25 Sales View Down, Stock Falls NEOG's Food Safety business witnesses a slight year-over-year decrease in revenues for the second quarter of fiscal 2025. zacks.com - 3 months ago
Neogen Corporation (NEOG) Q2 2025 Earnings Call Transcript Neogen Corporation (NASDAQ:NEOG) Q2 2025 Earnings Conference Call January 10, 2024 8:00 AM ET. seekingalpha.com - 3 months ago
Neogen (NEOG) Q2 Earnings Match Estimates Neogen (NEOG) came out with quarterly earnings of $0.11 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.11 per share a year ago. zacks.com - 3 months ago
Neogen Announces Preliminary¹ Second-Quarter 2025 Results Revenue of $231.3 million. Net loss of $456.3 million due to non-cash goodwill impairment; $(2.10) per diluted share. prnewswire.com - 3 months ago
Neogen® To Participate in Upcoming Investor Conferences LANSING, Mich. , Jan. 7, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG) announced today that the Company will participate in two upcoming investor conferences. prnewswire.com - 3 months ago
8. Profile Summary

Neogen Corporation NEOG

image
COUNTRY US
INDUSTRY Medical - Diagnostics & Research
MARKET CAP $ 1.7 B
Dividend Yield 0.00%
Description Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed producers and processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Contact 620 Lesher Place, Lansing, MI, 48912 https://www.neogen.com
IPO Date Aug. 23, 1989
Employees 2917
Officers Mr. Bill Waelke Head of Investor Relations Mr. John Edward Adent President, Chief Executive Officer & Director Sarah Demey Administrative Manager Mr. John Moylan Vice President, Corporate Controller & Chief Accounting Officer Ms. Amy M. Rocklin Ph.D. Chief Legal & Compliance Officer and Corporate Secretary Dr. Jason W. Lilly M.B.A., Ph.D. Chief Scientific Officer Mr. David H. Naemura Chief Operating Officer & Chief Financial Officer